These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34181208)

  • 1. Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday.
    Jiang R; Li JY; Zhu HY
    Curr Med Sci; 2021 Jun; 41(3):431-442. PubMed ID: 34181208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Bruton's Tyrosine Kinase in CLL.
    Ahn IE; Brown JR
    Front Immunol; 2021; 12():687458. PubMed ID: 34248972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline treatment in CLL: the case for time-limited treatment.
    Lévy V; Delmer A; Cymbalista F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Cherng HJ; Khwaja R; Kanagal-Shamanna R; Tang G; Burger J; Thompson P; Ferrajoli A; Estrov Z; Sasaki K; Sampath D; Wang X; Kantarjian H; Keating M; Wierda WG; Jain N
    Am J Hematol; 2022 Aug; 97(8):1005-1012. PubMed ID: 35567779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
    Eyre TA; Hori S; Munir T
    Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting initial therapy in CLL.
    Ahn IE; Brown JR
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):323-328. PubMed ID: 36485152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Markers in the Era of Targeted Therapies.
    Kang S; Ahn IE
    Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
    Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTK Inhibitors and Chemoimmunotherapy for CLL.
    Thompson P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
    [No Abstract]   [Full Text] [Related]  

  • 19. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.